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Abstract: To evaluate morphologic alterations in the thyroid gland in the second generation in cynomolgus monkeys, 
pregnant dams were exposed to high doses of thiamazole. In Experiment A, dams received thiamazole intragastrically 
via a nasogastric catheter from gestation day (GD) 50 to GD 150 or on the day before delivery. Initially, the dose level 
was 20 mg/kg/day (10 mg/kg twice daily); however, the dose level was subsequently decreased to 5 mg/kg/day (2.5 mg/
kg twice daily), since deteriorated general conditions were observed in two dams. Six out of seven neonates died on 
the day of birth. The cause of neonatal death was tracheal compression and suffocation from goiter. The transplacental 
exposure to thiamazole affected the fetal thyroid glands and induced goiter in all neonates. The surviving neonate was 
necropsied 767 days after discontinuation of thiamazole exposure and showed reversibility of the induced changes. In 
Experiment B, dams were intragastrically administered thiamazole at 5 mg/kg/day (2.5 mg/kg twice daily) for treatment 
periods from GDs 51 to 70, 71 to 90, 91 to 110, 111 to 130 and 131 to 150. All fetuses showed enlarged thyroid glands but 
were viable. Histopathologically, hypertrophy and/or hyperplastic appearance of the follicular epithelium of the thyroid 
gland was observed at the end of each treatment period. The most active appearance of the follicular epithelium, consist-
ing of crowded pedunculated structure, was demonstrated at end of the treatment period from GD 131 to 150. This is 
the first report on the morphology of fetal and neonatal goiter in the cynomolgus monkey. (DOI: 10.1293/tox.24.215; J 
Toxicol Pathol 2011; 24: 215-222)
Key words:  goiter, thiamazole, transplacental exposure, fetus, neonate, cynomolgus monkey
Introduction
Thiamazole, an antithyroid drug known as a synonym 
for methimazole, is a member of the thioamide group. It has 
been used for more than half a century to treat hyperthy-
roidism caused by Graves’ disease1, a condition in which 
the overactive thyroid gland produces excessive amounts 
of thyroid hormones. Thiamazole inhibits thyroid hormone 
synthesis stages, including the addition of iodine to thyro-
globulin by the enzyme thyroperoxidase, which is essential 
to the synthesis of thyroxine. Thiamazole has been the drug 
of choice for treatment of hyperthyroidism during pregnan-
cy and needs to be effectively managed and used to pre-
vent maternal, fetal and neonatal complications. A literature 
review showed that infants born to mothers whose condi-
tions had been managed with antithyroid drugs developed 
goiter1–5. However, there has been no report on the histo-
pathology of goiter in nonhuman primate fetuses and neo-
nates following administration of antithyroid drugs to dams. 
In the present study, we repeatedly administered relatively 
high doses of thiamazole to pregnant cynomolgus monkeys 
in the second and third trimesters of pregnancy to examine 
thyroidal morphological disorders in fetuses and neonates.
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Materials and Methods
Animals and housing conditions
Adult female cynomolgus monkeys (Macaca fascicu-
laris, age 3 to 8  years, body weight 2.6–5.4  kg, purpose 
bred) from China maintained in the primate facility of 
Drug Safety Research Laboratories, Shin Nippon Biomedi-
cal Laboratories, Ltd. (SNBL DSR), were used. Dams and 
offspring (after weaning) were individually provided with 
approximately 108 g (approximately 12 g × 9 pieces) and 
72 g (approximately 12 g × 6 pieces), respectively, of solid 
food (Teklad Global Certified 25% Protein Primate Diet, 
Harlan Sprague Dawley, Inc., Madison, WI, USA) once 
daily between 14:30 and 16:00. Any remaining food was re-
moved between 08:30 and 10:00 on the following day. Water 
conforming to the water quality standards required by the 
Japanese Waterworks Law was available ad libitum from 
an automatic supply (Edstrom Industries, Inc., Waterford, 
WI, USA). Stainless steel animal cages (Taiyo Stainless Co., 
Ltd., Kagoshima, Japan) conforming to USDA standards 
[690 mm (D) × 610 mm (W) × 750 mm (H)] were used. The 
number of animals per cage was one. Males and females 
were housed in pairs during the mating period. The animal 
rooms were maintained at a temperature of 23 °C to 29 °C 
and humidity of 35% to 75%, with artificial lightning for 12 
hours/day (06:00 to 18:00). The use of animals in this study 
was approved by the Institutional Animal Care and Use 
Committee of SNBL DSR, and the study was performed in 
accordance with the ethics criteria contained in the bylaws 
of the committee.
Mating and pregnancy diagnosis
Females that showed regular menstrual cycles were 
mated with males of proven fertility for three days between 
the 11th and 15th days of the menstrual cycle. When copula-
tion was confirmed visually, the median day of the mating 
period was designated as gestation day 0 (GD 0). On pre-
sumed GD 18, pregnancy was diagnosed by ultrasonogra-
phy (SSD-4000, Hitachi-Aloka Medical, Ltd., Tokyo, Japan) 
under sedation from an intramuscular injection of 10 mg/
kg of ketamine hydrochloride (Fuji Chemical Industry Co., 
Ltd., Saitama, Japan). Animal numbers were allotted in the 
order in which it was possible to confirm pregnancy (Ex-
periment A or B). Thereafter, pregnant animals underwent 
treatment with one of the dosing regimens stated below.
Treatment of dams
Experiment A: Ten dams received thiamazole (Sigma-
Aldrich Co., Ltd., Tokyo, Japan) intragastrically via a naso-
gastric catheter from GD 50 to GD 150 or on the day before 
delivery. Initially, the dose level was 20 mg/kg/day (10 mg/
kg twice daily); however, the dose level was subsequently 
decreased to 5 mg/kg/day (2.5 mg/kg twice daily), since de-
teriorated general conditions were observed in two dams. 
Thiamazole was administered twice a day, and the second 
administration was 6 hours after the first. All dams were 
observed four times a day during the treatment period and 
once a day during the nontreatment period and were to be 
allowed to deliver naturally.
Experiment  B:  Two  dams  per  group  were  adminis-
tered thiamazole (Sigma-Aldrich) at 5 mg/kg/day (2.5 mg/
kg twice daily) intragastrically via a nasogastric catheter for 
one of five different treatment periods. Thiamazole was ad-
ministered twice a day, and the second administration was 6 
hours after the first. Two or three animals were allocated to 
Groups 1, 2, 3, 4 and 5 as nontreated controls. The treatment 
periods for Groups 1, 2, 3, 4 and 5 were GDs 51 to 70, 71 
to 90, 91 to 110, 111 to 130 and 131 to 150, respectively. All 
dams were observed four times a day during the treatment 
period and once a day during the nontreatment period. Ce-
sarean section (CS) was performed on the day following the 
end of the relevant treatment period, and the treated fetuses 
were removed from the uterus.
Observations and examinations of second generation
All neonates were examined for viability, sex, body 
weight and external findings at birth. The offspring of Dam 
No. 7 in Experiment A was necropsied 767 days after birth. 
The thyroid glands collected from fetuses in Experiment B 
were weighed, and absolute and relative weights were cal-
culated from the relevant fetal body weight. The fetal and 
neonatal thyroid glands from Experiments A and B were 
fixed in 10% neutral buffered formalin for histopathologi-
cal examination. The specimens were embedded in paraf-
fin, sectioned and stained routinely with Hematoxylin-Eosin 
(HE) stain. Slide specimens were examined microscopical-
ly. Neonates No.3 and No.7 in Experiment A and all treated 
fetuses and one nontreated fetus from each group in Experi-
ment B were available for histopathological examination.
Examination of morphological parameters in the 
thyroid gland in Experiment B
Images of the thyroid were analyzed with analysis (Soft 
Imaging System GmbH, Muenster, Germany) software to 
determine the height of the follicular epithelium. The outer 
circumferences of the follicle and the lumen included in a 
one square millimeter section of each specimen were mea-
sured. The average radius and diameter of each were then 
calculated. The height of the follicular epithelium was cal-
culated by subtracting the lumen radius from the follicu-
lar radius. Pairwise comparisons were performed for each 
parameter by t-test based on a one-way ANOVA model. A 
value of p<0.05 was considered statistically significant.
Results
Experiment A
Clinical signs in dams and the viability outcomes for 
fetuses and neonates are shown in Table 1. Two dams (Nos. 
1 and 2) showed convulsion, prone position, external geni-
tal bleeding and/or low food consumption, and one of these 
dams (No. 1) then died on GD 70 and the other dam (No. 
2) aborted its fetus. Therefore, the dose level of thiamazole 
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5 mg/kg/day (2.5 mg/kg twice daily). After the decrease in 
dose level, one other dam (No. 4) showed low body weight, 
low food consumption and emaciation; however, this dam 
was able to maintain its pregnancy until the end of the 
third trimester, and no abnormalities in clinical signs were 
observed in the other seven dams (Nos. 3 and 5 to 10). At 
around the end of the gestation period, fetal death (No. 6) 
was detected by ultrasonography on GD 170, and six other 
dams (Nos. 3, 4, 5, 7, 9 and 10) were able to deliver natu-
rally. However, five out of the six neonates (Nos. 3, 4, 5, 
9 and 10) died on the day of birth, and only one neonate 
(No. 7) survived. All fetuses and neonates that had been vi-
able at the end of the third trimester showed swollen throat 
and presented palpable thyroid glands. Gross examination 
of this fetus and these neonates showed enlarged thyroid 
glands reaching the membranous wall of the trachea. His-
topathologically, the thyroid showed colloid storage and a 
flattened follicular epithelium. Neither cellular atypia nor 
mitotic figures were seen (Figs. 1a-e). The offspring (No. 
7) necropsied 767 days after birth showed no macroscopic 
abnormalities in the thyroid gland. Histopathologically, de-
position of brown pigment and proliferation of connective 
tissue were observed in this animal; however, no abnormal 
changes were observed in the follicular epithelium. Abso-
lute and relative thyroid gland weights in this offspring were 
1.42 g and 0.81 g/kg (body weight at necropsy: 1.76 kg), re-
spectively.
Experiment B
The results of Experiment B are shown in Tables 2 and 
3. No abortion or fetal death occurred during any thiam-
azole treatment period. All fetuses removed from uteri 
by cesarean section were viable. There was no difference 
in body weight between the control fetuses and the treat-
ed fetuses. All treated fetuses from Groups 1 to 5 showed 
enlarged thyroid glands (Fig. 2a–e). Absolute and relative 
thyroid weights in the treated fetuses were higher than those 
in the control fetuses. The follicular diameters, lumen di-
ameters and the heights of the follicular epithelium were 
significantly higher in treated fetuses than control fetuses. 
Although the height of the follicular epithelium did not show 
any apparent increase, the follicular diameter and lumen di-
Fig. 1.  Gross and histopathological findings in neonates in Experiment A. 1a: External appearance around the neck. 1b: Gross ap-
pearance of the thyroid gland. 1c: Cut surface of the thyroid gland. 1d: Thyroid gland reached the membranous wall of the 
trachea, HE stain. 1e: Follicles consisted of a flattened epithelium containing colloid, HE stain.Fetal and Neonatal Goiter in Cynomolgus Monkeys 218
ameter tended to increase as gestation progressed.
The histopathological appearances of the thyroid 
glands from each group are shown in Figs. 3a to 3e’. Mitotic 
figures were sporadically observed in the follicular epithe-
lium in treated fetuses from all groups. Hypertrophy and/
or hyperplasia of the thyroid follicular epithelium were dif-
fusely observed in treated fetuses from all groups. Follicular 
size was distinctly larger in the treated fetuses than in the 
control fetuses, with narrowed lumens. The follicular cells 
were more columnar than normal. Control thyroid glands 
examined at GD 72 and GD 91 consisted of a number of 
small follicles thought to be immature. Projections into the 
follicular lumen as a result of proliferation of the follicular 
epithelium were observed at GD 91. Large follicles lined by 
a low cuboidal follicular epithelium were observed at GD 
131. The follicular epithelium showed an active appearance 
with proliferated papillary projections into the follicular lu-
men and pedunculated structure at GD 151.
Discussion
Experiment A, thiamazole was administered at rela-
tively high doses for an antithyroid drug to pregnant cyno-
molgus monkeys during pregnancy to investigate morpho-
logic changes in fetuses and neonates. In Experiment B, 
morphologic changes in the fetal thyroid glands during the 
second and third trimesters were investigated sequentially 
with five different treatment periods to examine the effect 
of thiamazole. It has been reported that the drug induced hy-
pertrophy of the follicular epithelium in the thyroid glands 
of common marmosets (Callithrix jacchus)6. However, there 
has been no report of histopathological changes in nonhu-
man primate fetuses and neonates until now. The thyroid 
glands from fetuses exposed to thiamazole during the sec-
ond and third trimesters of pregnancy were compared mor-
phologically with those from control fetuses.
The thyroid gland is one of the organs most suscep-
tible to various intrinsic and extrinsic factors7, and the hypo-
thalamus-pituitary-thyroid axis and its hormonal feedback 
system involving TSH, triiodothyronine (T3) and thyroxine 
(T4) is well established.
Thiamazole, an antithyroid drug, is a member of the 
thioamide group. Thiamazole (1-methy-1H-imidazole-2-thi-
ol), whose chemical formula is C4H6N2S and whose molecu-
lar mass is 114.17 g/mol has been used for more than half 
a century to treat hyperthyroidism caused by Graves’ dis-
ease1, a condition in which the overactive thyroid gland pro-
duces excessive amounts of thyroid hormones. The working 
mechanism of thiamazole is based on inhibition of the addi-
tion of iodine to thyroglobulin by the enzyme thyroperoxi-
dase, an essential step in the synthesis of T3 and T4.
It has been reported that thionamide compounds are 
Table 1.  Experimental Designs and Results of Experiment A
Thiamazolea) Dam 
animal 
No.
GD Clinical signs of dams Delivery status
Neonate  
animal 
No.
Body weight 
at birth (g)
Viability Sex
External 
findings 20 mg/kg 5 mg/kg
Treated period (days)
20 - 1 - Prone position (GD69), exter-
nal genital bleeding (GD70), 
dam death (GD70)
Abortion (GD70) 1 NE Dead NE NE
33 - 2 - Convulsion (GD69-71), prone 
position (GD69), low food 
consumption (GD70~)
Abortion (GD83) 2 NE Dead NE NE
7 108 3 165 No abnormal changes Neonatal death 3 245 Dead M Swelling, 
throat
7 111 4 168 Low body weight, low food 
consumption, emaciation
Neonatal death 4 249 Dead M Swelling, 
throat
3 127 5 180 No abnormal changes Neonatal death 5 320 Dead F Swelling, 
throat
2 118 6 - No abnormal changes Fetal death 
(GD170)
6 NE Dead F Swelling, 
throat
- 118 7 168 No abnormal changes No abnormal 
changes
7 331 Alive F Swelling, 
throat
- 40 8 - No abnormal changes Abortion (GD90) 8 NE Dead NE NE
- 120 9 170 No abnormal changes Neonatal death 9 302 Dead F Swelling, 
throat
- 92 10 142 No abnormal changes Neonatal death 10 197 Dead M Swelling, 
throat
a) Dose 20 mg/kg/day → 5 mg/kg/day. Thiamazole was administered on GD 50 to 150 or on the day before delivery. The dose level was de-
creased to 5 mg/kg/day, since deteriorated general conditions were observed in two dams (Animal Nos. 1 and 2). GD: Gestation day. NE: Not 
examined. M: Male. F: Female.Yoshikawa, Moriyama, Kodama et al. 219
among the most potent inhibitors of thyroid hormones and 
that they have induced hyperplasia of the thyroid gland in 
experimental animals8. This effect occurs when the admin-
istration of the drug reduces thyroid hormones to subnormal 
levels and the resultant increase in circulating TSH stimu-
lates enlargement of the thyroid gland.
The cynomolgus monkey, a widely used nonhuman 
primate model, has similar reproductive physiology, endo-
Fig. 2.  Gross appearance of changes in the thyroid glands of fetuses in Experiment B with 5 different treatment periods. All fetuses in 
thiamazole exposure Groups 1 to 5 showed swollen throats. 2a: Treatment period GD 51 to 70; fetuses removed on Day 71. 2b: 
Treatment period was GD 71 to 90; fetuses removed on Day 92. 2c: Treatment period GD 91 to 110; fetuses removed on Day 
111. 2d: Treatment period GD 111 to 130; fetuses removed on Day 131. 2e: Treatment period GD 131 to 150; fetuses removed 
on Day 151.
Table 2.  Experimental Designs and Results of Experiment B
Group
Dam 
animal No.
Dose 
 (mg/kg)
Dosing days  
(GD)
CS*  
day
Neonate  
animal No.
Viability Sex
Fetal weight  
(g)
Organ weight (Thyroid)
Absolute 
weight (mg)
Relative  
weight (mg/g)
1
Control-1 - - 72 Control-1
Alive
F 33.1 13.0 0.39
Control-2 - 72 Control-2 M 22.3 5.4 0.24
101 5 51–70 71 101 F 33.8 135.0 3.99
102 71 102 F 32.4 180.0 5.56
2
Control-3 - - 91 Control-3 M 84.2 18.0 0.21
Control-4 - 91 Control-4 M 77.1 27.6 0.36
201 5 71–90 91 201 M 61.0 185.4 3.04
202 92 202 M 89.7 531.8 5.93
3
Control-5
-
- 110 Control-5 M 165.0 64.0 0.39
Control-6 - 110 Control-6 M 157.5 48.3 0.31
Control-7 - 111 Control-7 M 150.5 30.3 0.20
301 5 91–110 110 301 F 170.0 360.0 2.12
302 111 302 M 162.0 316.0 1.95
4
Control-8 - - 131 Control-8 M 228.5 56.0 0.25
Control-9 - 131 Control-9 M 273.2 123.2 0.45
401 5 111–130 131 401 F 256.3 840.0 3.28
402 131 402 M 260.5 341.0 1.31
5
Control-10 - - 151 Control-10 M 307.4 50.0 0.16
Control-11 - 155 Control-11 F 363.0 147.0 0.40
501 5 131–150 152 501 M 332.4 560.0 1.68
502 151 502 F 363.9 533.5 1.47
GD: Gestation day. M: Male. F: Female. *: Caesarean section.Fetal and Neonatal Goiter in Cynomolgus Monkeys 220
crinology and development to the human9,10. The human 
gestation period is around 40 weeks, while that of the cyno-
molgus monkey is around 160 days10. Organogenesis occurs 
during the first trimester in both the cynomolgus monkey 
and the human, between GDs 21 and 50 and GDs 18 and 
60, respectively9,10. It has been reported that the develop-
ment of the human thyroid gland begins from GD 2111, and 
that the human thyroid gland is well developed by GD 70 
in the first trimester and begins concentrating iodide and 
producing thyroid hormones at this time11. Compounds with 
a molecular weight greater than 1000 Da do not cross the 
placenta easily, whereas those of less than 600 Da, including 
thiamazole, freely cross the placenta2–4,12–14. In the present 
study, an excessive dosage of thiamazole affected the fetal 
thyroid glands through the placenta, inducing goiter in fe-
tuses or neonates.
Fetal, neonatal or maternal death or abortion occurred 
in Experiment A. It was considered that the cause of death 
was respiratory impairment following severe compression 
of the trachea by an enlarged thyroid gland, as has been re-
ported in humans1,2. Compression of the cervical region by 
an excessively enlarged thyroid gland is considered poten-
tially lethal to neonates.
One offspring (No. 7), which showed a swollen throat 
at birth, was necropsied on Day 767. Although no abnormal 
changes were observed macroscopically, its absolute thyroid 
gland weight was above the range of the control background 
data (unpublished data) of our laboratories. This organ 
weight result in this animal showed that even at the age of 
two years, thyroid gland weights had not returned to normal, 
a finding similar to that reported in rats15. Moreover, there 
were no abnormal changes in the follicular cells. Histopath-
ological changes observed in the interstitium of the thyroid 
gland were considered traces of goiter at birth. Regression 
of goiter induced in fetuses was observed when antithyroid 
compounds including propylthiouracil (PTU) were with-
drawn, enabling reversibility of the induced changes2,15,16.
In Experiment B, there were no nonviable outcomes 
for fetuses or abnormalities in fetal body weight. All treated 
fetuses from each group that underwent treatment for one of 
five periods showed goiter. The detection of fetal goiter dur-
ing pregnancy in a mother on antithyroid drug therapy by 
ultrasonography is an indication of fetal hypothyroidism1–3.
High absolute and relative thyroid organ weights were 
noted in treated fetuses in all groups when compared with 
control fetuses. These high organ weights were considered 
to be due to the increase in size of the follicle and the col-
loid, since both the follicular and lumen diameters increased 
as gestation progressed.
Although the mean height of the follicular epithelium 
in the treated groups did not show any apparent increase 
in morphometry examinations, both diffuse hyperplasia 
and hypertrophy of the thyroid follicular epithelium were 
observed in the histopathological examination. In Group 4 
(GD 111 to 130 treatment period), around the midpoint of 
the third trimester, an inactive appearance of the follicular 
epithelium was seen. This was considered to indicate that 
the susceptibility to thiamazole in this group was not as 
great as in the other groups. In contrast to those from Group 
4 (GD 111 to 130 treatment period), the fetal thyroids from 
Group 5 (GD 131 to 150 treatment period) demonstrated the 
most characteristic appearance of thiamazole treatment-
related changes. The follicular epithelium appeared active, 
consisting of papillary projections into the follicular lumens 
that had become pedunculated. This observation suggests 
that administration of thiamazole to dams just before deliv-
ery strongly induces histopathological changes in the fol-
licular epithelium of the thyroid gland in the fetal cynomol-
gus monkey. Although TSH and thyroid hormones were not 
assessed in the present study, the morphologic features of 
the thyroid glands from treated fetuses were consistent with 
enhanced resorption of colloid through TSH stimulation17.
In conclusion, this is the first report on macroscopic 
and histopathological investigations of goiter in cynomolgus 
monkey fetuses and neonates when dams received relatively 
high doses of thiamazole during the second and third tri-
mesters of pregnancy.
Table 3.  Morphological Parameters in the Thyroid Gland in Experiment B
Group 1 2 3 4 5
Dose (mg/kg) - 5 - 5 - 5 - 5 - 5
Dosing days (GD) - 51–70 - 71–90 - 91–110 - 111–130 - 131–150
Follicular diameter (µm) 36.09 89.53* 44.25 115.71* 69.35 123.45* 96.85 156.16* 65.90 164.13*
Lumen diameter (µm) 27.29 56.15* 35.47 83.49* 54.75 86.17* 77.99 123.96* 47.36 128.19*
Height of follicular epithelium (µm) 4.40 16.69* 4.39 16.11* 7.30 18.64* 9.43 16.10* 9.27 17.97*
GD: Gestation day. Values are expressed as averages. *: Significantly different from the control (P<0.05).
Fig. 3.  Histologic appearance of changes in the thyroid glands of fetuses in Experiment B with 5 different treatment periods, HE stain. 3a: In-
duced change in the thyroid gland at GD 71. 3a’: Control thyroid gland at GD 72. 3b: Induced change in the thyroid gland at GD 91. 3b’: 
Control thyroid gland at GD 91. 3c: Induced change in the thyroid gland at GD 111. 3c’: Control change in the thyroid gland at GD 111. 
3d: Induced change in the thyroid gland at GD 131. 3d’: Control thyroid gland at GD 131. 3e: Induced change in the thyroid gland at GD 
151. 3e’: Control thyroid gland at GD 151.Yoshikawa, Moriyama, Kodama et al. 221
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